A recent pilot study offers cautious optimism regarding the potential of low-dose lithium to slow cognitive decline associated with mild cognitive impairment (MCI), particularly in individuals with amyloid-beta deposits – a hallmark of Alzheimer’s disease. While the trial, conducted at the University of Pittsburgh School of Medicine, did not meet its prespecified statistical significance thresholds for primary outcomes, researchers found the treatment was safe and well-tolerated, and observed preliminary signals of benefit in verbal memory.
The study, which ran from February 2018 to August 2024 with a two-year follow-up, involved 80 participants aged 60 and older diagnosed with MCI. Participants were randomly assigned to receive either daily low-dose lithium carbonate or a placebo for two years. The research team examined cognitive performance, brain volume, and levels of brain-derived neurotrophic factor, among other measures. The findings suggest a potential avenue for delaying cognitive deterioration, offering a relatively low-cost and accessible strategy, though further investigation is crucial.
Lithium’s Impact on Verbal Memory
The most notable finding centered on verbal memory. Participants receiving lithium exhibited a slower rate of decline in verbal memory compared to those on the placebo – a decrease of 0.73 points annually versus 1.42 points in the placebo group, representing a difference of 0.69 points per year (95% CI, 0.01-1.37; P = .05) [2]. This effect was particularly pronounced in individuals who tested positive for amyloid-beta, suggesting a neuroprotective effect in those at higher risk for Alzheimer’s disease [5]. Researchers emphasize that lithium doesn’t restore lost memory but may act as a “brake,” slowing the rate of inevitable decline [5].
“Lithium has been a mainstay for treating bipolar disorder for over half a century, but new research suggests its benefits may extend deep into neuroprotection,” according to Neuroscience News [5]. The study builds upon previous observations indicating that individuals with bipolar disorder who have been on long-term lithium treatment often maintain better brain integrity as they age [5].
Study Design and Safety Profile
The randomized, double-blind, placebo-controlled pilot trial included 41 participants in the lithium group and 39 in the placebo group. Researchers carefully monitored participants for safety, and the study confirmed that low-dose lithium is safe and well-tolerated in older adults [4]. The trial successfully recruited and retained participants, demonstrating the feasibility of conducting larger studies [4]. The study design involved a single site at the University of Pittsburgh School of Medicine [2]. Of 170 individuals assessed, 83 were randomized, with 80 ultimately starting treatment [2]. Data analysis took place from August 2024 to December 2025 [2].
Coprimary Outcomes and Future Research
Despite the encouraging findings regarding verbal memory, none of the six prespecified coprimary outcomes – including cognitive performance on tests like the California Verbal Learning Test-II, hippocampal volume, and cortical gray matter volume – reached statistical significance [1, 2]. Mean baseline scores on the California Verbal Learning Test-II were comparable between groups (7.95 for lithium vs. 7.90 for placebo) [2]. Researchers acknowledge that the study’s limitations, including its relatively small sample size, necessitate larger, more comprehensive trials to confirm these preliminary findings [1].
The study’s findings are guiding larger studies aimed at evaluating lithium’s potential for Alzheimer’s prevention [1]. Further research will be essential to determine the optimal dosage, duration of treatment, and identify which individuals are most likely to benefit from low-dose lithium therapy [1].
The exploration of existing medications for new applications, like lithium in the context of MCI, represents a promising and cost-effective approach to addressing the growing global burden of Alzheimer’s disease and related dementias. What comes next will be larger, multi-center trials designed to validate these initial observations and refine our understanding of lithium’s neuroprotective mechanisms.
Have you or a loved one been affected by mild cognitive impairment? Share your experiences in the comments below. Please also share this article with anyone who might find this information helpful.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
